{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:58:39Z","timestamp":1790531919253,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18ck0106463h0001"],"award-info":[{"award-number":["18ck0106463h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19mk0101091h0003"],"award-info":[{"award-number":["19mk0101091h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.lungcan.2022.08.018","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:47:29Z","timestamp":1662464849000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients"],"prefix":"10.1016","volume":"173","author":[{"given":"Mayu","family":"Ohuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Yagishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Inaba Higashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2022.08.018_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/psp4.12130","article-title":"Translational Pharmacokinetic\/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab","volume":"6","author":"Lindauer","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"19","key":"10.1016\/j.lungcan.2022.08.018_b0010","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.lungcan.2022.08.018_b0015","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.lungcan.2022.08.018_b0020","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lungcan.2022.08.018_b0025","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.lungcan.2022.08.018_b0030","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2000.18.3.684","article-title":"Phase I clinical trial design in cancer drug development","volume":"18","author":"Eisenhauer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.lungcan.2022.08.018_b0035","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1200\/JCO.2014.58.1082","article-title":"Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies","volume":"33","author":"Tosi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.lungcan.2022.08.018_b0040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bjc.2017.473","article-title":"Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection","volume":"118","author":"Viala","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2022.08.018_b0045","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2022.08.018_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2022.08.018_b0055","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00262-021-02997-2","article-title":"Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab","volume":"71","author":"Jo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"10.1016\/j.lungcan.2022.08.018_b0060","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lungcan.2022.08.018_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.018_b0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00228-021-03199-6","article-title":"Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients","volume":"78","author":"Abe","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.018_b0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/psp4.12139","article-title":"Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors","volume":"6","author":"Ahamadi","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.lungcan.2022.08.018_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002344","article-title":"Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors","volume":"9","author":"Hurkmans","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.018_b0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.xphs.2018.10.064","article-title":"Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non-Small Cell Lung Cancer","volume":"108","author":"Li","year":"2019","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.lungcan.2022.08.018_b0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","article-title":"Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response","volume":"44","author":"Li","year":"2017","journal-title":"Journal of pharmacokinetics and pharmacodynamics"},{"issue":"1","key":"10.1016\/j.lungcan.2022.08.018_b0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","article-title":"A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2022.08.018_b0100","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1158\/1078-0432.CCR-11-1081","article-title":"Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients","volume":"17","author":"Azzopardi","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lungcan.2022.08.018_b0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-018-3728-z","article-title":"Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(\u00ae)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors","volume":"83","author":"Quartino","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.lungcan.2022.08.018_b0110","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00280-019-03771-z","article-title":"Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers","volume":"83","author":"Osawa","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.lungcan.2022.08.018_b0115","article-title":"Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC","volume":"1","author":"Miyawaki","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.lungcan.2022.08.018_b0120","article-title":"Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer","author":"Inaba Higashiyama","year":"2022","journal-title":"Journal of Thoracic Oncology"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:01:19Z","timestamp":1759237279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222006080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"alternative-id":["S0169500222006080"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}